ACLXGBX Institutional Ownership

ARCELLX INC

ACLXGBX institutional ownership at a glance

Follow ARCELLX INC institutional ownership through recent Schedule 13G and 13D filings. Compare reported shares, ownership percentages, filing dates, and changes in beneficial ownership over time.

Latest filing: T. Rowe Price Investment Management filed Schedule 13G amendment on Mar 6, 2026, reporting 2.7M shares and 12.00% beneficial ownership.

Browse recent ownership filings How Schedule 13G works Why a 13G is not a trade report

How to read Schedule 13 ownership changes

Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.

Form 13F rows are quarter-end holding context only and do not establish an exact entry date.

For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.

Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.

Cross-institution intelligence

Institutional Research

This gauge summarizes recent agreement across tracked institutional activity.

Latest filing Mar 6, 2026

Public consensus preview Reduction leaning 30/100 institutional research score

2 tracked institutions Latest filing Mar 6, 2026

1 reducing across 1 comparable institution.

Accumulating0

Unchanged0

Reducing1

Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week range data is not available for this security yet.

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Feb 28, 2026

Fidelity / FMR Mar 6, 2026 filed

T. Rowe Price Investment Management Mar 6, 2026 filed

Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists, portfolio tools, and the first live gauge on the default tracker. Investor or Pro reveals research gauges across tracker views and unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 5 filing(s) · 2 older require more history access

Holder	Observed / filed	Reported change	Shares	Ownership
T. Rowe Price Investment Management CIK0001897612	Feb 28, 2026 observed Mar 6, 2026 filed · 6d Schedule 13G amendment	Reported reduction	2.7M -7.9M	12.00% -6.30 pts
Fidelity / FMR CIK0000315066	Feb 27, 2026 observed Mar 6, 2026 filed · 7d Schedule 13G amendment	Earliest Schedule 13G amendment found	309	12.00%
T. Rowe Price Investment Management CIK0001897612	Dec 31, 2025 observed Feb 17, 2026 filed · 48d Schedule 13G amendment	Reported accumulation	10.6M +955.8K	18.30% +1.70 pts

Explore more institutional activity

Related research

Compare ACLXGBX with other securities showing similar institutional activity or recent accumulation across several tracked institutions.

Similar institutional activity

REPL Replimune Group, Inc. 30/100 Reduction leaning CPRI CAPRI HOLDINGS LTD 30/100 Reduction leaning OCFC OCEANFIRST FINANCIAL CORP 30/100 Reduction leaning PCRX Pacira BioSciences, Inc. 30/100 Reduction leaning

Recent multi-institution accumulation

OCGN OCUGEN INC 2 accumulating Aug 7, 2026 DNTH Dianthus Therapeutics, Inc. /DE/ 2 accumulating Aug 7, 2026 SRPT Sarepta Therapeutics, Inc. 2 accumulating Aug 7, 2026 RARE ULTRAGENYX PHARMACEUTICAL IN 2 accumulating Aug 7, 2026